Combined targeting of EZH2, MYC and YAP/TAZ can, therefore, effectively de-repress expression of tumor suppressors and concurrently repress the expression of oncogenic pathways, to ultimately inhibit tumor growth. The gene discussed is EZH2; the disease is neoplasm.